Synonyms: chidamide | CS-055 | CS055 | HBI-8000
tucidinostat is an approved drug (China)
Compound class:
Synthetic organic
Comment: Tucidinostat (chidamide) is an orally active inhibitor of histone deacetylase (HDAC) enzymes [4]. It has some subtype selectivity for HDAC isoenzymes 1, 2, 3 and 10. Note that we show this compound with no specified stereochemistry.
|
|
No information available. |
Summary of Clinical Use |
Chidamide was developed and tested in China, where it now has regulatory approval for the treatment of cancers. Preclinical studies have shown efficacy in various types of cancer, such as pancreatic cancer [5], colon cancer [4], hepatocellular carcinoma cells [6] and leukemias [2,7]. Phase 1 clinical trial results are reported in [1]. Results from a Phase 3 study using tucidinostat plus exemestane (an aromatase inhibitor) in patients with advanced, hormone receptor-positive, HER2 negative breast cancer were published in 2019 [3]. Progression-free survival was improved using this treatment combination compared to exemestane alone. |
Mechanism Of Action and Pharmacodynamic Effects |
Chidamide is an inhibitor of histone deacetylase (HDAC) activity, which increases acetylation of histone H3. This leads to downstream activation of the PI3K/Akt and MAPK/Ras signaling pathways and ultimately results in cell cycle arrest and apoptosis [4]. |